Immune stimulation in scleroderma patients treated with thalidomide

Clinical Immunology

Volumn 97, Issue 2, 2000, Pages 109-120

  Oliver, Stephen J ^a   Moreira, Andre ^a,b   Kaplan, Gilla ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

GM CSF; IL 12; Immune modulation; Scleroderma; Th1 Th2 cytokines; Thalidomide; Ulcer healing

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA;

EID: 0033769659     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2000.4920     Document Type: Article

References (49)

1. Clinical aspects of systemic and localized scleroderma
2. Immunopathogenesis of systemic sclerosis
3. Cytokine production and serum levels in systemic sclerosis
4. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma
5. In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases
6. Type 2 helper T-cell predominance and high CD 30 expression in systemic sclerosis
7. Sequential dermal microvascular and perivascular changes in the development of scleroderma
8. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations
9. Soluble interleukin-2 receptor, interleukin-2 and interleukin- 4 in sera and supernatants from patients with progressive systemic sclerosis
10. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL- 13 in patients with systemic sclerosis
11. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis
12. Scleroderma-like changes due to chronic graft-versus-host disease
13. Scleroderma, Sjogren-like syndrome, and chronic graft-versus-host disease
14. Microchimerism and the pathogenesis of systemic sclerosis
15. The immune system: Effector and target of graft-versus-host disease
16. Thalidomide for the treatment of chronic graft-versus-host disease
17. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model
18. Therapy of chronic graft-v-host disease in a rat model
19. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
20. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity
21. + subset
22. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
23. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee
24. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis
25. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis
26. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus
27. Recalcitrant pyoderma gangrenosum: Treatment with thalidomide
28. Pyoderma gangrenosum associated with Behcet's disease: Treatment with thalidomide
29. Pyoderma gangrenosum associated with Behcet's syndrome - Response to thalidomide
30. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial
31. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group
32. Thalidomide increases human keratinocyte migration and proliferation
33. Keratinocyte growth regulation by the products of immune cells
34. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing
35. GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skin in vivo
36. Randomized, double-blind, placebo-controlled, dose-ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers
37. Successful treatment of aphthous ulcerations in AIDS patients using topical granulocyte-macrophage colony-stimulating factor
38. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
39. Antigen-driven but not lipopolysaccharide-driven IL- 12 production in macrophages requires triggering of CD40
40. Interleukin-12 inhibits murine graft-versus-host disease
41. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis
42. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents
43. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma
44. Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation
45. Selective inhibition of human diploid fibroblast collagen synthesis by interferons
46. Antagonistic effects of interferon-gamma and interleukin-4 on fibroblast cultures
47. Recombinant cytokine treatment for scleroderma. Can the antifibrotic potential of interferon-gamma be realized clinically?
48. Interferon-gamma in the treatment of systemic sclerosis: A randomized controlled multicentre trial